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Breast cancer is the second largest disease affecting women worldwide. It remains 
the most frequently reported and leading cause of death among women in both 
developed and developing countries. Tamoxifen and raloxifene are commonly used 
selective estrogen receptor modulators for treatment of breast cancer in women 
with high risk, although resistance occurs by tamoxifen after 5  years of therapy 
and both drugs cause uterine cancer and thromboembolic events. Aromatase 
inhibitors (AIs) are one of the optional modes used for breast cancer treatment. The 
combination of AIs along with tamoxifen can also be beneficial. Various therapeutic 
agents from different sources are being studied, which further need to be improved 
for potential outcome. For this, clinical trials based on large number of patients 
with optimal dose and lesser side effects have to be more in practice. Despite the 
clinical trials going on, there is need of better molecular models, which can identify 
high risk population, new agents with better benefit having less side effects, and 
improved biomarkers for treating breast cancer.
Keywords: breast cancer, chemoprevention, aromatase inhibitors, epidermal growth factor receptor, estrogen 
receptor, biomarker
inTRODUCTiOn
Breast cancer is the second leading cause of death in the female population worldwide. Each year, 
200,000 new cases of invasive breast cancer are diagnosed (1). Breast cancer comprises 22.9% of all 
cancers worldwide (2). The survival rates and prognosis for breast cancer are mostly dependent on 
the type of cancer, stages, treatment, and the ethnicity and location of the patient. High survival 
Abbreviations: AIs, aromatase inhibitors; AP-1, activator protein-1; EGFR, epidermal growth factor receptor; ER, estrogen 
receptor; H2AX, H2A histone family, member X; HIF, hypoxia-inducible factor-1α; NF-κB, nuclear factor kappa-light-chain-
enhancer of activated B cells; PARP, poly-ADP ribose polymerase; ROS, reactive oxygen species; SAHA, suberoylanilide 
hydroxamic acid; SERM, selective estrogen receptor modulators; STAT3, signal transducer and activator of transcription 3; 
TGF, transforming growth factor.
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rates have been observed in breast cancer cases of western world 
as compared to developing countries where survival rates are 
less. Out of 10 women, 8 or more (85%) in England having breast 
cancer survive for at least 5 years. There are a number of factors 
responsible for causing breast cancer. Dietary factors, such as 
high-fat diet, alcohol intake, smoking, obesity, higher levels of 
cholesterol, and iodine deficiency have high risk of cancer occur-
rence. In females, lack of breastfeeding and childbearing make 
them more susceptible to disease. About 9% cancer cases can be 
prevented by changing diet and body weight, e.g., Japanese women 
have less rate of breast cancer than Americans but when they shift 
their place, risk increases. European Prospective Investigation 
into Cancer has shown that menopausal women having more fat 
are at high risk, high carbohydrate diet also increase the risk of 
breast cancer. People who ate fish, dairy products, fiber, fruits, 
vegetables, flavonoids, and antioxidants have low risk (3). Asian 
women who eat more soy foods have low risk of breast cancer. In 
a cohort study in USA, 10 g of pure alcohol a day is limited for 
women and 20 g for men (4). Smoking is another factor, which 
increases the risk of breast cancer, especially those who smoke 
at an early age in their life have risk as high as 35–50% (5, 6). 
There are other risk factors involved in cancer occurrence, such 
as chemicals biphenyls, solvents of organic nature, hydrocarbons, 
pesticide use, radiation, and hazardous shift work.
Genetics has an important role in breast cancer. In about <5% 
of cases, breast–ovarian cancer syndrome occurs by inheritance 
including women having BRCA1 and BRCA2 mutation. The 90% 
of total genetics account to these mutations with a breast cancer 
risk of 60–80% affected cases. BRCA1 mutations predispose 
women to breast and ovarian cancers. BRCA1 in breast cancer 
has higher aneuploidy number than tumors, which do not have 
mutations in BRCA1 (7, 8). The next section discusses the 
molecular alterations during breast cancer, how various therapies 
and agents can prevent breast cancer, and how these agents can be 
modulated with better efficacy and positive outcome in treatment 
of the disease.
MOLeCULAR ALTeRATiOnS in BReAST 
CAnCeR
Cell Cycle Deregulation in Cancer
The growth and differentiation of a cell is controlled by a regu-
lated cell cycle. If there is uncontrolled proliferation of cells, it 
leads to cancer. This results in abnormal functioning of tissues, 
organ system in an organism. The cell cycle has checkpoints, 
which check the entry of cell from one phase to another phase and 
whether the functions are completed in each phase or not. These 
checkpoints are controlled by genes, which help in stimulating or 
inhibiting the cell division. These are proto-oncogenes and tumor 
suppressor genes. The cell cycle-dependent kinases are regulated 
by cyclins present in a cell and are required for cell division. They 
are regulated by CDK inhibitors, such as INK4 proteins and p21 
and p27 of Cip and Kip family. The deregulation of CDKs results 
in uncontrolled proliferation and genomic defects in DNA repair 
mechanisms and DNA damage checkpoints and chromosomal 
instability. Mitotic checkpoints and DNA damage alterations 
cause increase in function of CDK, which leads to initiation of 
tumor. The cell cycle regulatory signals are not controlled as in a 
normal process of cell cycle. This leads to deregulated cell cycle, 
mutations, and genetic abnormalities (9).
ROLe OF ePiDeRMAL GROwTH FACTOR 
ReCePTOR in BReAST CAnCeR
Epidermal growth factor receptor is from ErbB class of tyros-
ine kinase cell surface-based receptor including HER2, neu, 
or ErbB2 (10). The epidermal growth factor receptor family 
comprises four cell surface receptors, EGFR are HER1, HER2 
or neu, HER3, and HER4 types. The binding of growth factor to 
receptor activates its dimerization with other members of ErbB, 
such as HER2, and phosphorylation occurs. This makes binding 
sites available for cytosolic proteins containing Src homol-
ogy 2 (SH2) domains and leads to stimulation of downstream 
factors activating mitogen-activated protein kinase pathway, 
which causes cell to re-enter S-phase of cell cycle, consequently 
resulting in cell proliferation (11). The ligands of EGFR include 
transforming growth factor α (TGF-α), amphiregulin, epigen, 
betacellulin, heparin binding factor, and epiregulin (12). EGFR 
amplification, increase in copy number of gene occurs in 15–30% 
of breast cancer cases. This results in poor prognosis in patients 
and decreased survival rate (13–15).
ROLe OF H2AX (H2A HiSTOne FAMiLY, 
MeMBeR X) in BReAST CAnCeR
H2AFX is the genes coding histone H2A protein. The H2A, H2B, 
H3, and H4 are histone proteins present in two copies and form 
a histone octamer. The DNA is wrapped around these histones 
and forms nucleosome. DNA damage response is activated upon 
DNA damage in cells. Double-strand breaks activate phospho-
rylation of histone variant H2AX, which repairs DNA by activat-
ing proteins at damaged chromatin and at checkpoints arresting 
cell cycle. γ-H2AX helps to develop cancer therapies (9, 16, 17). It 
also occurs due to other factors, such as shortened telomeres and 
hypoxia (18). It has been found that in triple negative, in BRCA1 
and p53-mutated breast cancer γ-H2AX level is more (19), and 
in triple negative, the chance of errors are more in DNA damage 
repair pathway (20). DNA damage response signaling is marked 
by γH2AX in familial breast tumors and in ER, PR, ERBB2-triple 
negative breast carcinoma.
ROLe OF POLY ADP RiBOSe 
POLYMeRASe in BReAST CAnCeR
PARP1 is a protein which repairs single-strand breaks in the 
DNA. PARP1 is also involved in differentiation, proliferation, and 
tumor transformation (21). It decreases the ATP level of a cell 
upon repairing DNA damage which results in lysis and cell death 
(necrosis). It also causes programmed cell death by production of 
PARP, which activates mitochondria to release apoptosis induc-
ing factor. PARP inactivation occurs by enzymes caspases or 
cathepsins, which cause cleavage of PARP. The cleavage fragments 
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tell which cell death pathway is activated. Double-strand DNA 
breaks are repaired by homologous recombination repair path-
way having BRCA1 and BRCA2 proteins. If they are mutated, it 
causes errors in repair of DNA resulting in breast cancer. PARP1 
protein repairs single-strand breaks; if it is not repaired, it causes 
double-strand breaks. There are drugs which are used as PARP 
inhibitors. PARP inhibitors are used in cancer cells with mutated 
BRCA1 and BRCA2 proteins. Cancer cells are sensitive to PARP 
inhibitors. Iniparib, olaparib, and rucaparib are some of the PARP 
inhibitors used for breast cancer (22).
ROLe OF p53 in BReAST CAnCeR
Tumor suppressor protein, p53 is encoded by the TP53 gene in 
humans, which functions to inhibit cell proliferation to regulate 
cell cycle. It is known as the guardian of the genome as it maintains 
the cellular stability by preventing genetic mutation. In normal 
cells, low level of p53 is maintained by continuous degradation 
via Mdm-2, which is an ubiquitin ligase. The p53 activation 
occurs when there is a cellular stresses, such as DNA damage 
(23), phosphorylation of p53 occurs due to which it is no longer 
degraded by Mdm-2 and hence accumulates. Post-translational 
modifications stimulate the protein for DNA binding, transac-
tivating downstream effector genes which regulate the action of 
tumor suppressor p53. Upon DNA damage or cellular stress, p53 
is known to activate apoptosis or cell cycle arrest. It has major role 
in cancer as it maintains genomic stability, anti-antigenic effects, 
manages tumor inflammation, and immune response. TP53 is 
mutated mostly in 50% of all human cancers and in 20–30% of 
breast cancers with more than 15,000 different mutations. About 
30% of the TP53 mutations are because of genetic changes in 
breast cancer. It varies with tumor subtype (24, 25). The mutant 
p53 affects various other proteins in a cell leading to metastasis.
ReACTive OXYGen SPeCieS in 
BReAST CAnCeR
Reactive oxygen species (ROS) contain oxygen reacting molecules 
and regulate cell signaling and homeostasis (26). It is generated 
and eliminated at the same time in normal process, balanced by 
scavenging system. Due to environmental stress, such as UV or 
heat exposure, ROS levels increase, damaging cell causing car-
boxylation of cellular proteins and peroxidation of lipids resulting 
in carcinogenesis. ROS level can decide the difference between 
tumor and non-tumor cells. In cancer cells, stress causes increase 
in metabolism, mitochondrial dysfunction and in levels of ROS 
(27, 28). ROS in cancer cell stimulates several transcription fac-
tors, such as NF-κB, AP-1, HIF-1α, ATF 3, and STAT3, leading to 
expression of protein for cell growth, defense, and survivability 
including cell proliferation, invasion leading to metastasis (29). 
ROS is useful for survival of cancer cells in moderate level and 
in excessive level, kills cancer cells. If there is increased level 
of oxidative stress in mitochondria, cytochrome c is released, 
apoptosis occurs, and stimulation of caspases leads to cell death 
resulting in stimulation of c-Jun N-terminal kinases (JNKs). 
JNK phosphorylates and downregulates the Bcl-2 and Bcl-XL, 
anti-apoptotic proteins. This leads to damage to mitochondrial 
membrane (30). The molecular alterations in breast cancer are 
triggered by cascade of reaction in a cell and are dependent on 
one another. ROS are produced by metabolic activities of cell and 
cytotoxic drugs. DNA damage by ROS activates PARP-1, which in 
turn organizes DNA repair by modifications of proteins, such as 
histones and helicases. PARP leads to decrease in NAD, ATP level 
in cell resulting in cell death and necrosis regulated by p53, which 
induced apoptosis and senescence upon exposure to ROS (31).
BiOMARKeRS AS A TOOL FOR BReAST 
CAnCeR
The upcoming studies are in practice based on whole genome 
arrays collection from patients, such as next-generation 
sequencing (NGS). Ion torrent sequencing is used for cancer 
DNA sequencing, which is less expensive (32). DNA and RNA 
sequencing is done from tumors based on exomes or candidate 
genes, which identifies somatic mutations and malignant trans-
formation in significantly mutated genes SMG (33). In cancer 
genome atlas data, genes mutated in luminal A, B, and basal such 
as breast cancer are listed, TP53, PIK3CA, MAP3K1, and PTEN, 
which are used as a therapeutic tool in triple negative breast 
cancer. Somatic mutation in cancer based on copy number, aber-
rations, nucleotide substitutions, and on subsets in breast cancer 
BRCA1/2 are found by dGene, DGIdb HER2, and ESR1 estrogen 
receptor (ER) gene mutations for finding a drug or kinase inhibi-
tor. Patient-derived xenograft is used now as a genomic model 
to avoid genetic drift, which should have larger sample size (34). 
The microarray data and the samples of biological use can be 
saved in an independent bio bank to identify new prognostic or 
predictive biomarkers and drug targets. PARP inhibitors are new 
drugs given as a single therapy or in combination with various 
agents of DNA damage such as radiation therapy. These inhibitors 
have fewer side effects and are used to treat aggressive cancers, 
such as cancers involving hereditary BRCA1/2 and triple negative 
breast and ovarian cancer. PARP inhibitor biomarkers, such as 
olaparib for patients with BRCA1/2-mutant tumors, ovarian, and 
colorectal cancers; iniparib for breast and lung cancers; rucaparib 
for breast and ovarian cancer; and veliparib for melanoma and 
breast cancer, are used. The crosstalk of DNA repair pathways 
occur, which requires combination of DNA repair biomarkers. 
The discovery of biomarkers has led to develop effective cure with 
beneficial clinical outcome (35).
THeRAPeUTiC APPROACHeS FOR 
BReAST CAnCeR
Chemotherapy
Chemotherapy is used in ER-negative breast cancer (ER−) 
occurring in stages 2–4. The chemotherapeutic drugs are given 
in combinations for about a period of 3–6  months. One com-
bination is known as AC, which is combination of cyclophos-
phamide with doxorubicin (adriamycin) (36). Another class of 
drugs are taxanes, in which docetaxel and taxotere are used in 
combinations known as CAT (37). CMF is the combination of 
cyclophosphamide, methotrexate, and fluorouracil. Cisplatin or 
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methotrexate as single agents or lipoic acid and hydroxycitrate 
combined together or used alone is not as effective as lipoic acid, 
hydroxycitrate, and cisplatin or methotrexate combined together. 
It targets metabolic pathway in cancer associated with classical 
chemotherapy (38).
Monoclonal Antibodies
HER2 is a tyrosine kinase-based cell receptor of epidermal 
growth factor group, which is overexpressed in some of the 
breast cancer cells. In breast cancer, the disease recurs and 
has less prognosis in about 25–30% cases where HER2 gene 
and its protein is overexpressed (39). As an adjuvant therapy, 
monoclonal antibody trastuzumab (Herceptin) is used to 
treat HER2-positive breast cancers which are in stages 1–3 
and has benefited about 87% of patients for 5-year survival 
(40). Trastuzumab binds to HER2 overexpressing cancer cells, 
thereby blocks effectively growth of breast cancer. Trastuzumab 
is expensive and causes serious side effects. About 2% of 
patients undergoing treatment with this drug suffer significant 
heart damage. It is used for patients having metastasis as a 
combination with chemotherapy or as monotherapy, lapatinib 
is used first in combination with letrozole or HER2, ER (+) 
breast cancer patients as well for HER2 (+) in combination with 
capecitabine (41).
Hormonal Therapy
Hormones are naturally occurring substances in the body whose 
function is to work as chemical messengers. There are various 
approaches, which have been used to treat hormone responsive 
breast cancer.
Blocking Ovarian Function
Ovaries are the primary source of estrogen in premenopausal 
women. By eliminating or suppressing ovarian function, estrogen 
levels are reduced. Ovarian function when inhibited is called as 
ovarian ablation. It is permanent in which ovaries are removed 
called as oophorectomy or by treating with surgery and radiation. 
Another method is suppression of ovaries with drugs, which is not 
a permanent treatment and is called as gonadotropin (GnRH) or 
luteinizing hormone releasing hormone (LH-RH) agonists. They 
inhibit the ovaries to produce estrogen and prevents stimulus 
from the pituitary gland. The U.S. Food and Drug Administration 
has approved drugs for ovarian ablation, which are goserelin and 
leuprolide (42).
Blocking Estrogen Production
In breast cells, estrogen helps in cell growth. Estrogen is made in 
the ovaries and tissues by aromatase enzyme. Estrogen binds to 
ER on the surface of cell. ERs reside on the surface, in cytoplasm, 
and in nucleus. When estrogen molecules are not present, these 
receptors are inactive but once the estrogen molecule enters cell, 
the estrogen binds to its receptors causing change in conformation 
of receptor. ER complex binds at their DNA-binding sites called 
as estrogen response elements. As a neoadjuvant therapy, drugs 
are used to inhibit the function of an enzyme called aromatase. 
They are given in postmenopausal women. The drug is used in 
combination in order to suppress ovarian function, as ovaries 
produce more aromatase and cannot be blocked by inhibitors in 
premenopausal women (43). Anastrozole and letrozole are the 
aromatase inhibitors (AIs) both of which inhibit aromatase for 
short period, while exemestane permanently inhibits the enzyme.
Blocking Estrogen’s Effects
There are various drugs which intervene with estrogen action 
to activate the growth of breast cancer cells. SERMs are agents 
modulating function of estrogen in tissues. ERs are activated or 
inhibited in different tissues. The function of SERMs varies in dif-
ferent tissues depending on chemical structure of selective estro-
gen receptor modulator (SERM) as an antagonist in breast tissue 
and agonist in other tissues, such as bone and uterus. Tamoxifen 
in breast functions as an antagonist and in uterus as agonist. It has 
been found that the amount of co-activator 1 (SRC-1 and NCOA1) 
is in excess amount in uterus as compared to breast. Raloxifene 
in both acts as an antagonist. It has been found that raloxifene 
potentially enlists co-repressor proteins and in uterus acts as an 
antagonist. The three main drugs that act SERMs are tamoxifen 
(Nolvadex), raloxifene (Evista), and toremifene (Fareston) (44). 
Other antiestrogen drugs: fulvestrant (Faslodex) upon binding 
to the ER acts as an estrogen antagonist as SERMs, but it acts 
as antiestrogen, which upon binding to ER, causes destruction 
of receptor and same does not occur in SERMs. Fulvestrant is 
used with other antiestrogens in combination and with AIs such 
as anastrozole, letrozole, and exemestane in ER postmenopausal 
women having metastasis.
Aromatase inhibitors
Aromatase inhibitors are used to inhibit endogenous formation 
of estrogen from androgens. These act by inhibiting the function 
of the aromatase enzyme complex, which catalyzes this conver-
sion (45). The activity of enzyme is inhibited by binding to it, 
leading to the formation of inactive enzyme, which is incapable 
of binding on its actual site of androgen substrate. Aromatase 
forms estrogen in ovaries and in several tissues of the body. First 
AI, formestane, was used to compare tamoxifen treatment and 
its effect in clinical trials and had same effect as of tamoxifen. 
The other AIs including anastrozole, letrozole, and exemestane 
(46, 47) had increased efficiency when studied in combination in 
various clinical trials than tamoxifen alone. The AIs, anastrozole 
and letrozole, are given as first-line drugs to postmenopausal 
hormone-sensitive women in the advanced stages of breast can-
cer (48). AIs are not given to premenopausal women, as they are 
not able to inhibit the enzyme as it is formed more in ovaries of 
these women. The drugs are effective when given in combination 
with other drugs that inhibits ovarian function in these women. 
There are few side effects of AI, such as blood clots, stroke, bone 
loss, and heart problem. The main modalities of treating breast 
cancer, which are described in Figure  1, can be improved by 
pharmacological studies of therapies and drugs. In therapeutic 
agents, preclinical studies need to be validated in clinical studies 
with factors, such as large sample number, less toxicity, and com-
binatorial studies. Hormonal therapy also requires more sample 
number, less toxicity, and optimal dose. Monoclonal antibodies 
and non-hormonal therapy are more toxic, which can be replaced 
by use of biomarkers where we need to check efficacy, toxicity, 
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FiGURe 1 | Figure showing various therapeutic options for breast cancer management. Adjuvant therapy is given after surgery or main treatment and may 
include radiation or chemical therapy. Neoadjuvant therapy is given before main treatment. Other therapeutics is in experimental phase.
and avoid intra-heterogeneity in breast cancer patients. Other 
therapeutic agents in use are suberoylanilide hydroxamic acid 
(SAHA), second generation compound, and a histone deacetylase 
inhibitor. SAHA reduces growth, causes cell cycle arrest, and 
apoptosis in breast cancer cells of human (49).
AGenTS COMMOnLY USeD FOR BReAST 
CAnCeR COnTROL
Natural compounds have been used in treatment of breast 
cancer, for example, luteolin in herbs, such as thyme, parsley, 
and vegetables, such as celery and broccolis, are used in women 
who have taken hormone replacement therapy. Luteolin reduces 
vessels feeding cancer cells. In another study, chemical nutrients 
were tested in broccoli, grapes, apples, tofu, and turmeric root 
(50). The compounds curcumin, isoflavone, indole-3-carbinol, 
c-phycocyanin, resveratrol, and quercetin used in combination 
were effective in reducing breast cancer cell growth by 80% and 
there was no effect on control cells (51). Some of natural com-
pounds are listed in Table 1.
There are various other agents which are used in combination 
with tamoxifen in breast cancer. Some of the agents are mentioned 
in Table 1.
COnCLUSiOn
Antiestrogen and estrogen therapies are developed with better 
outcome by finding out markers which can differentiate between 
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TABLe 1 | (A) Selective natural compounds used in breast cancer therapy; (B) selective preclinical and clinical studies of novel agents for breast cancer  
prevention.
(A) SeLeCTive nATURAL COMPOUnDS USeD in BReAST CAnCeR THeRAPY
Compound Source Studies effect Reference
Flavonoid
Honokiol Magnolia officinalis and Magnolia 
grandiflora
ER+ MCF-7, MDA-MB-231 ER− breast cancer It arrests cell cycle, leads to apoptosis in 
cancer cells, and acts as antioxidant
(52)
Magnolol Magnolia officinalis and Magnolia 
obovata
MDA-MB-231 It causes cell cycle arrest, apoptosis, and 
acts as antiproliferative agent
(53)
Sesquiterpenes
Costunolide Inula helenium, Saussurea lappa, 
and Magnolia grandiflora
MCF-7, MDA-MB-231 It arrests cell cycle leads to apoptosis in 
cancer cells, and acts as antioxidant
(54)
Parthenolide Tanacetum parthenium, Tanacetum 
vulgare, Centaurea ainetensis, 
Tanacetum larvatum, and 
Helianthus annuus
MCF-7, MDA-MB-231 It arrests cell cycle, leads to apoptosis 
in cancer cells, and acts as antioxidant. 
Cytotoxic
(55)
Diterpenoids
Pseudolaric acid B Pseudolarix kaempferi MCF-7, MDA-MB-231 It arrests cell cycle, leads to apoptosis in 
cancer cells, and acts as antioxidant
(56)
Oridonin Isodon rubescens MCF-7, MDA-MB-231 It arrests cell cycle, leads to apoptosis 
in cancer cells, and acts as antioxidant. 
Autophagic agent
(57)
Polyphenolic
Wedelolactone Eclipta alba, Wedelia 
calandulaceae, and Wedelia 
chinensis
MDA-MB-231,468 It arrests cell cycle, leads to apoptosis in 
cancer cells, and acts as antioxidant
(58)
Alkaloids
Evodiamine Evodia rutaecarpa MCF-7 It arrests cell cycle, leads to apoptosis 
in cancer cells, and acts as antioxidant, 
antimetastatic, and anticarcinogenesis
(59)
(B) SeLeCTive PReCLiniCAL AnD CLiniCAL STUDieS OF nOveL AGenTS FOR BReAST CAnCeR PRevenTiOn
Drugs/agents Studies: in vitro, in vivo, trials effect on breast cancer Source Reference
Beta-lactam MCF-7 and MDA MB-231 breast 
cancer cells, xenograft mouse 
model
It inhibits proliferation of breast cancer cells and 
tumor growth in mouse model. Beta lactamase 
linked affinity reagents based on cancer cell fusion 
peptides can be used directly in targeted enzyme 
prodrug development in cancer
β-lactam ring are group of antibiotics 
such as penicillins, carbapenems, and 
monobactams
(60–63)
Triphenylethylenes ER-positive MCF-7 and the 
ER-negative breast cancer cell line 
T47D, BALB/c athymic mice
It is used for breast cancer treatment, examples 
are tamoxifen, idoxifene, and toremifene. 
Tamoxifen is used in ER+ breast cancer, its dose 
20 mg/day is optimized in ongoing clinical trials to 
reduce toxicity
Non-steroidal antiestrogens  (64)
Letrozole MCF-7 breast cancer cells, MCF-
7Ca tumor xenograft models and 
BALB/c athymic nude mice
BIG 1-98 study group clinical trial 
compared letrozole and tamoxifen 
drug in breast cancer patients
It is used in local or advanced breast cancer 
having hormone receptor positive. It is used in 
combination with tamoxifen with improved overall 
survival
Non-steroidal aromatase inhibitor (65, 66)
Anastrozole Murine breast cancer cells (4T1) in 
female BALB/c mice
ATAC clinical trial compared 
anastrozole and tamoxifen for 
treatment of breast cancer
The combination trial of ATAC showed that it 
has more efficiency and less side effects than 
tamoxifen and can be used as initial treatment for 
postmenopausal women with ER+ breast cancer
Non-steroidal aromatase inhibitor (67)
Cyclosporin A Multidrug-resistant human breast 
cancer cells MCF-7-adriamycin-
resistant (AdrR), female athymic 
nude BALB/c mice
It lowers levels of glucosylceramide in multidrug-
resistant cells which are given tamoxifen. 
It functions as a chemoresponsive agent. 
Pharmacokinetics of docetaxel in combination 
of CsA showed active and safer use for treating 
advanced breast cancer in Phase II study
It is an immunosuppressant drug (68, 69)
(Continued)
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Verapamil BALB/c mouse murine breast 
cancer cells (4T1-R)
It inhibits multi drug resistance rendering 
cells sensitive to chemotherapy at an optimal 
concentration of 6 and 1–2M
It functions as an L-type calcium blocker 
from group of phenylalkylamine
(70, 71)
Suramin MDA-MB-231 cells, xenografted 
human, athymic mice
The drug binds to TGF, EGFR, FGF, PDGF, and 
IGF causing impaired growth of cell and is used 
for breast cancer treatment. In combination 
with paclitaxel, it is effective and non-cytotoxic 
in metastatic breast cancer at 10 and 50 μmol/l 
concentrations in phase I and II trials
It functions as an antagonist of P2 
receptors which are ATP-stimulated G 
protein-coupled receptors
(72, 73)
Flaxseed MCF-7 breast cancer cells, 
ovariectomized mice, nude mice
It inhibits the growth of human estrogen-
dependent breast cancer in athymic mice, and it 
enhances the inhibitory effect of tamoxifen. Dietary 
flaxseed reduces tumor growth in breast cancer 
and is less expensive and available
Flaxseed (FS) is rich in mammalian lignan 
precursors and α-linolenic acid, which 
have anticancer effects
(74, 75)
Plumbagin Human breast cancer cell MDA-
MB-23, female BALB/c mice
Plumbagin reduces cancer cell growth and 
osteoclast formation in the bone of mice
It was isolated form plant plumbago (76)
EGFR, epidermal growth factor; TGF, transforming growth factors alpha and beta; FGF, fibroblast growth factors; PDGF, platelet-derived growth factor; IGF, insulin-like growth 
factors; ATAC, anastrozole, tamoxifen combination trial.
Phases I and II breast cancer to overcome resistivity of  different 
sets of drug. Anticancerous drugs are given in high doses, 
assumed on the basis of population studies. The pharmaco-
logical approach which decides the nature and mode of action of 
chemotherapy is in need of standardization of dose and response 
to a drug with better efficiency and less toxicity. A set of new 
biomarkers for breast cancer are needed to improve risk factors. 
Clinical trials need to be done in population having high risk 
with large samples and longer follow-up. The side effects and 
dose is needed to evaluate for different set of population having 
diversity. The chemoprevention and other therapeutic agents can 
be improved by keeping in mind above factors by physicians, 
oncologists, and patients. There is a need of molecular models 
for identification of high risk factors to identify new agents with 
more benefit ratio and less toxicity as a drug development 
program. Various approaches, such as improved clinical trials, 
combinatorial approach of different drugs, gene expression stud-
ies, and pharmacokinetics, will benefit right patients with right 
kind of drugs.
AUTHOR COnTRiBUTiOnS
SA: draft and writing, design, concept, editing; NM: design, 
concept, editing and approved; HC: draft and writing; MR: edit-
ing; PNP: editing; MAK: editing; MM: writing; GAS: writing; JJ: 
editing; AA: writing; MSJ: design, concept, editing, and approved.
TABLe 1 | Continued
ReFeRenCeS
1. Rebecca Siegel MPH, Deepa Naishadham MA, Ahmedin Jemal DV. Cancer 
statistics. Am Cancer Soc (2013) 404:320–33. 
2. Winnieciadkhar, Bernard J. Mammography. Int J Pharm Bio Sci (2013) 
2:1106–11. doi:10.1.1.302.681 
3. Cancer Research UK. Breast Cancer. London, UK: Cancer Research UK (2014).
4. Cao Y, Willett WC, Rimm EB, Stampfer MJ, Giovannucci EL. Light 
to  moderate intake of alcohol, drinking patterns, and risk of cancer: 
results from two prospective US cohort studies. BMJ (2015) 351:h4238. 
doi:10.1136/bmj.h4238 
5. Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, 
et al. Active smoking and second hand smoke increase breast cancer risk: the 
report of the Canadian expert panel on tobacco smoke and breast cancer risk. 
Tob Control (2011) 20(1):e2. doi:10.1136/tc.2010.035931 
6. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of 
physical inactivity on major non-communicable diseases worldwide: an 
analysis of burden of disease and life expectancy. Lancet (2012) 9838:219–29. 
doi:10.1016/S0140-6736(12)61031-9 
7. Marty D. Boris Pasche: cancer genetics cancer treatment and research. J Genet 
Couns (2010) 21:353–4. doi:10.1007/s10897-011-9423-4 
8. Gage M, Wattendorf D, Henry LR. Translational advances regarding hered-
itary breast cancer syndromes. J Surg Oncol (2012) 5:444–51. doi:10.1002/
jso.21856 
9. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, 
Lukas J, et al. ATM activation in normal human tissues and testicular cancer. 
Cell Cycle (2005) 6:838–45. doi:10.4161/cc.4.6.1742 
10. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of 
non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 
10:947–55. doi:10.1056/NEJMct0807960 
11. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 
(2009) 36015:1579. doi:10.1056/NEJMra0707704 
12. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation 
to tumor development: EGFR gene and cancer. FEBS J (2010) 2:301–8. 
doi:10.1111/j.1742-4658.2009.07448.x 
13. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, et al. EGFR gene 
amplification in breast cancer: correlation with epidermal growth factor 
receptor mRNA and protein expression and HER-2 status and absence of 
EGFR-activating mutations. Mod Pathol (2005) 8:1027–33. doi:10.1038/
modpathol.3800438 
14. Breast Cancer Organisation. Breast Cancer. Camberwell: Breast Cancer 
Organisation (2014).
15. National Cancer Institute. Breast Cancer. Bethesda: National Cancer Institute 
(2014).
16. Burma S, Chen BP, Murphy M. ATM phosphorylates histone H2AX in 
response to DNA double-strand breaks. J Biol Chem (2001) 45:42462–7. 
doi:10.1074/jbc.C100466200 
17. Yu T, MacPhail SH, Banath JP, Klokov D, Olive PL. Endogenous expression of 
phosphorylated histone H2AX in tumors in relation to DNA double-strand 
breaks and genomic instability. DNA Repair (Amst) (2006) 5:935–46. 
doi:10.1016/j.dnarep.2006.05.040 
18. Nakamura AJ, Redon CE, Bonner WM, Sedelnikova OA. Telomere-dependent 
and telomere-independent origins of endogenous DNA damage in tumor 
cells. Aging (Albany NY) (2006) 2:212–8. 
March 2016 | Volume 6 | Article 458
Ali et al. Breast Cancer Treatment Strategies
Frontiers in Oncology | www.frontiersin.org
19. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen 
T. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex 
in human breast cancer: MRE11 as a candidate familial cancer-predisposing 
gene. Mol Oncol (2008) 4:296–316. doi:10.1016/j.molonc.2008.09.007 
20. Tommiska J, Bartkova J, Heinonen MM, Hautala L, Kilpivaara O, Eerola H. 
The DNA damage signalling kinase ATM is aberrantly reduced or lost in 
BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. 
Oncogene (2008) 17:2501–6. doi:10.1038/sj.onc.1210885 
21. McGlynn P, Lloyd RG. Replicating past lesions in DNA. Mol Cell (2002) 
10(4):700–1. doi:10.1016/S1097-2765(02)00687-1 
22. Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol (2011) 
5:373–4. doi:10.1038/nbt0511-373 
23. McBride OW, Merry D, Givol D. The gene for human p53 cellular tumor 
antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U 
S A (1986) 1:130–4. doi:10.1073/pnas.83.1.130 
24. Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, et al. 
Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer 
(2013) 132(5):1227–31. doi:10.1002/ijc.27767 
25. Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, et al. 
p53 in breast cancer subtypes and new insights into response to chemotherapy. 
Breast (2013) 2:S27–9. doi:10.1016/j.breast.2013.07.005 
26. Dickinson BC, Tang Y, Chang Z, Chang CJ. A nuclear-localized flu-
orescent hydrogen peroxide probe for monitoring sirtuin-mediated 
oxidative stress responses in vivo. Chem Biol (2011) 8:943–8. doi:10.1016/j.
chembiol.2011.07.005 
27. Ramsey MR, Sharpless NE. ROS as a tumour suppressor. Nat Cell Biol (2006) 
11:1213–5. doi:10.1038/ncb1106-1213 
28. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, et al. 
Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce 
irreversible cellular senescence. Nat Cell Biol (2006) 11:1291–7. doi:10.1038/
ncb1491 
29. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and 
downsides of reactive oxygen species for cancer: the roles of reactive oxygen 
species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 
(2012) 11:1295–322. doi:10.1089/ars.2011.4414 
30. Wiman KG. p53 talks to PARP: the increasing complexity of p53-induced cell 
death. Cell Death Differ (2013) 20:1438–9. doi:10.1038/cdd.2013.111 
31. Liou G-Y, Storz P. Reactive oxygen species in cancer. Free Radic Res (2014) 
44(5):479–96. doi:10.3109/10715761003667554 
32. Liu S, Wang H, Zhang L, Tang C, Jones L, Ye H, et  al. Rapid detection of 
genetic mutations in individual breast cancer patients by next generation DNA 
sequencing. Hum Genomics (2015) 9:2. doi:10.1186/s40246-015-0024-4 
33. Craig DW, O’Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, et al. 
Genome and transcriptome sequencing in prospective metastatic triple-neg-
ative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 
(2013) 12:104. doi:10.1158/1535-7163.MCT-12-0781 
34. Goncalves R, Warner WA, Luo J, Ellis MJ. New concepts in breast cancer 
genomics and genetics. Breast Cancer Res (2014) 16:460. doi:10.1186/
s13058-014-0460-4 
35. Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP 
inhibitor therapies. Am J Cancer Res (2011) 1(3):301–27. 
36. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene 
expression profiles predict complete pathologic response to neoadjuvant 
paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemo-
therapy in breast cancer. Am Soc Clin Oncol (2004) 12:2284–93. doi:10.1200/
JCO.2004.05.166 
37. Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, et  al. 
Integrated modeling of clinical and gene expression information for per-
sonalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 
22:8431–6. doi:10.1073/pnas.0401736101 
38. Guais A, Baronzio G, Sanders E, Campion F, Mainini C, Fiorentini G, et al. 
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to 
chemotherapy improves effectiveness against tumor development: experimen-
tal results and case report. Invest New Drugs (2010) 30:200–11. doi:10.1007/
s10637-010-9552-x 
39. Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, et  al. 
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary 
inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, 
single-arm phase 2 study. Lancet Oncol (2012) 4:375–84. doi:10.1016/
S1470-2045(12)70049-9 
40. Bao T, Zhang R, Badros A, Lao L. Acupuncture treatment for bortezo-
mib-induced peripheral neuropathy: a case report. Pain Res Treat (2011) 
2011:920807. doi:10.1155/2011/920807 
41. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. 
Randomized study of lapatinib alone or in combination with trastuzumab in 
women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
J Clin Oncol (2010) 21:4437. doi:10.1200/JCO.2008.21.4437 
42. Emens LA, Davidson NE. Postoperative endocrine therapy for 
invasive breast cancer. Cancer Treat Res (2009) 151:139–61. 
doi:10.1007/978-0-387-75115-3_10 
43. Vogel VG. Update of the national surgical adjuvant breast and bowel 
project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing 
breast cancer. Cancer Prev Res (2010) 6:696–706. doi:10.1158/1940-6207.
CAPR-10-0076 
44. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, 
Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 
and 2010: a systematic analysis. Lancet (2011) 378:1461–84. doi:10.1016/
S0140-6736(11)61351-2 
45. Brodie AM, Schwarzel WC, Shaikh AA, Brodie HJ. The effect of an aromatase 
inhibitor, 4-hydroxy-4-androstene-3, 17-dione, on estrogen-dependent pro-
cesses in reproduction and breast cancer. Endocrinology (1977) 6:1684–95. 
doi:10.1210/endo-100-6-1684 
46. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D. Mature results 
of a randomized phase II multicenter study of exemestane versus tamoxifen as 
first-line hormone therapy for postmenopausal women with metastatic breast 
cancer. Ann Oncol (2003) 9:1391–8. doi:10.1093/annonc/mdg362 
47. Rocío G-B, Nancy S, Lorenza D, Javier C. Mechanisms of resistance to endo-
crine therapy in breast cancer: focus on signaling pathways, miRNAs and 
genetically based resistance. Int J Mol Sci (2013) 14(1):108–45. doi:10.3390/
ijms14010108  
48. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier 
A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of 
advanced breast cancer in postmenopausal women: analysis of survival and 
update of efficacy from the International Letrozole Breast Cancer Group. 
J Clin Oncol (2003) 11:2101–9. doi:10.1200/JCO.2003.04.194 
49. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential 
 therapeutic agent for human breast cancer treatment. Mol Med (2000) 
11:849–66. 
50. Cook MT, Liang Y, Besch-Williford C, Goyette S, Mafuvadze B, Hyder SM. 
Luteolin inhibits progestin-dependent angiogenesis, stem cell-like charac-
teristics, and growth of human breast cancer xenografts. Springerplus (2015) 
4:444. doi:10.1186/s40064-015-1242-x 
51. Ouhtit A, Gaur RL, Abdraboh M, Ireland SK, Rao PN, Raj SG, et  al. 
Simultaneous inhibition of cell cycle, proliferation, survival, metastatic 
pathways and induction of apoptosis in breast cancer cells by a phytochemical 
super  –  cocktail: genes that underpin its mode of action. J Cancer (2013) 
4(9):703–15. doi:10.7150/jca.7235 
52. Chilampalli S, Zhang X, Fahmy H, Kaushik RS, Zeman D, Hildreth MB, et al. 
Chemopreventive effects of honokiol on UVB-induced skin cancer develop-
ment. Anticancer Res (2010) 30:777–83. 
53. Hou X, Yuan X, Zhang B, Wang S, Chen Q. Screening active anti-breast cancer 
compounds from cortex Magnolia officinalis by 2D LC-MS. J Sep Sci (2013) 
36:706–12. doi:10.1002/jssc.201200896 
54. Choi YK, Seo HS, Choi HS, Kim SR, Shin YC, Ko SG. Induction of Fas-
mediated extrinsic apoptosis, p21WAF1-related G2/M cell cycle arrest and 
ROS generation by costunolide in estrogen receptor-negative breast cancer 
cells, MDA-MB-231. Mol Cell Biochem (2012) 363:119–28. doi:10.1007/
s11010-011-1164-z 
55. Wyrebska A, Szymanski J, Gach K, Piekielna J, Koszuk J, Janecki T, et  al. 
Apoptosis-mediated cytotoxic effects of parthenolide and the new synthetic 
analog MZ-6 on two breast cancer cell lines. Mol Biol Rep (2013) 40:1655–63. 
doi:10.1007/s11033-012-2215-6 
56. Yu JH, Cui Q, Jiang YY, Yang W, Tashiro S, Onodera S, et  al. Pseudolaric 
acid B induces apoptosis, senescence, and mitotic arrest in human 
breast cancer MCF-7. Acta Pharmacol Sin (2007) 28:1975–83. 
doi:10.1111/j.1745-7254.2007.00706.x 
March 2016 | Volume 6 | Article 459
Ali et al.  Breast Cancer Treatment Strategies
Frontiers in Oncology | www.frontiersin.org
57. Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M, et al. Oridonin induces apop-
tosis, inhibits migration and invasion on highly-metastatic human breast can-
cer cells. Am J Chin Med (2013) 41:177–96. doi:10.1142/S0192415X13500134 
58. Benes P, Knopfova L, Trcka F, Nemajerova A, Pinheiro D, Soucek K, et  al. 
Inhibition of topoisomerase IIalpha: novel function of wedelolactone. Cancer 
Lett (2011) 303:29–38. doi:10.1016/j.canlet.2011.01.002 
59. Jiang J, Hu C. Evodiamine: a novel anti-cancer alkaloid from Evodia rutae-
carpa. Molecules (2009) 14:1852–9. doi:10.3390/molecules14051852 
60. Nathwani SM, Hughes L, Greene LM, Carr M, O’Boyle NM, McDonnell S, 
et  al. Novel cis-restricted β-lactam combretastatin A-4 analogues display 
anti-vascular and anti-metastatic properties in  vitro. Oncol Rep (2012) 
29:585–94. doi:10.3892/or.2012.2181  
61. Shukla GS, Krag DN. Novel beta-lactamase-random peptide fusion 
libraries for phage display selection of cancer cell-targeting agents suit-
able for enzyme prodrug therapy. J Drug Target (2010) 18(2):115–24. 
doi:10.3109/10611860903244181 
62. Chen D, Falsetti SC, Frezza M, Milacic V, Kazi A, Cui QC, et al. Anti-tumor 
activity of N-thiolated beta-lactam antibiotics. Cancer Lett (2008) 268(1):63–9. 
doi:10.1016/j.canlet.2008.03.047 
63. Bissantz C, Kuhn B, Stahl M. A medicinal chemist’s guide to molecular inter-
actions. J Med Chem (2010) 53(14):5061–84. doi:10.1021/jm100112j 
64. Lee ES, Schafer JM, Yao K, England G, O’Regan RM, De Los Reyes A, et al. 
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 
in tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer 
Res (2000) 6(12):4893–9. 
65. Brodie A, Sabnis G, Jelovac D. Aromatase and breast cancer. J Steroid Biochem 
Mol Biol (2007) 102(1–5):97–102. doi:10.1016/j.jsbmb.2006.09.002 
66. Abrial C, Durando X, Mouret-Reynier MA, Thivat E, Bayet-Robert M, Nayl 
B, et  al. Role of neo-adjuvant hormonal therapy in the treatment of breast 
cancer: a review of clinical trials. Int J Gen Med (2009) 2:129–40. doi:10.2147/
IJGM.S4172 
67. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of 
anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 
10-year analysis of the ATAC trial. Lancet Oncol (2010) 11(12):1135–41. 
doi:10.1016/S1470-2045(10)70257-6 
68. Xanthopoulos JM, Romano AE, Majumdar SK. Response of mouse breast can-
cer cells to anastrozole, tamoxifen, and the combination. J Biomed Biotechnol 
(2005) 1:10–9. doi:10.1155/JBB.2005.10 
69. Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, 
Huitema AD, et  al. Phase II and pharmacological study of oral docetaxel 
plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. 
Curr Clin Pharmacol (2014) 9(2):139–47. doi:10.2174/15748847086661311
11193403 
70. McCarthy M, Auda G, Agrawal S, Taylor A, Backstrom Z, Mondal D, et al. In 
vivo anticancer synergy mechanism of doxorubicin and verapamil combina-
tion treatment is impaired in BALB/c mice with metastatic breast cancer. Exp 
Mol Pathol (2014) 1:6–15. doi:10.1016/j.yexmp.2014.04.013 
71. Yui H, Imaizumi U, Beppu H, Ito M, Furuya M, Arisaka H, et al. Comparative 
effects of verapamil, nicardipine, and nitroglycerin on myocardial 
ischemia/reperfusion injury. Anesthesiol Res Pract (2011) 2011:521084. 
doi:10.1155/2011/521084 
72. Singla AK, Bondareva A, Jirik FR. Combined treatment with paclitaxel 
and suramin prevents the development of metastasis by inhibiting meta-
static colonization of circulating tumor cells. Clin Exp Metastasis (2016) 
6:705–14. doi:10.1007/s10585-014-9661-6 
73. Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, et al. Phase I/II trial 
of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic 
breast cancer treated with prior taxanes. Cancer Chemother Pharmacol (2012) 
70:49–56. doi:10.1007/s00280-012-1887-x 
74. Chen J, Hui E, Ip T, Thompson LU. E2 blood level. Dietary flaxseed enhances 
the inhibitory effect of tamoxifen on the growth of estrogen-dependent human 
breast cancer (mcf-7) in nude mice. Clin Cancer Res (2004) 10(22):7703–11. 
doi:10.1158/1078-0432.CCR-04-1130 
75. American Institute for Cancer Research. Flaxseed. Washington, DC: American 
Institute for Cancer Research (2010).
76. Yan W, Wang TY, Fan QM, Du L, Xu JK, Zhai ZJ, et al. Plumbagin attenuates 
cancer cell growth and osteoclast formation in the bone microenvironment of 
mice. Acta Pharmacol Sin (2014) 35:124–34. doi:10.1038/aps.2013.152 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Ali, Mondal, Choudhry, Rasool, Pushparaj, Khan, Mahfooz, Sami, 
Jarullah, Ali and Jamal. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
